Engineering hairy cellulose nanocrystals for chemotherapy drug capture.
Engineering hairy cellulose nanocrystals for chemotherapy drug capture.
复制标题
工程毛状纤维素纳米晶体用于化疗药物捕获。
DOI：
10.1016/j.mtchem.2021.100711
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Sheikhi,Amir
中科院分区：
文献类型：
--
作者：
Young,SarahAE;Muthami,Joy;Pitcher,Mica;Antovski,Petar;Wamea,Patricia;Murphy,RobertDenis;Haghniaz,Reihaneh;Schmidt,Andrew;Clark,Samuel;Khademhosseini,Ali;Sheikhi,Amir
癌症是全球主要死亡原因之一，每年影响数百万人。尽管化疗仍然是世界上最常见的癌症治疗方法之一，但化疗药物的严重副作用给癌症患者带来了严重的担忧。在许多情况下，可以进行局部化疗以最大限度地发挥药物作用；然而，药物全身循环会引起不良副作用。在这里，我们开发了一种高效的纤维素基纳米吸附剂，在生理条件下，每克吸附剂可以捕获超过 6,000 毫克的阿霉素 (DOX)，这是最广泛使用的化疗药物之一。这种药物捕获能力比其他纳米吸附剂（例如基于 DNA 的平台）高出 3,200% 以上。我们展示了阴离子毛状纤维素纳米晶体（也称为静电稳定纳米晶体纤维素 (ENCC)）如何与人血清中带正电的药物结合并立即捕获 DOX，而不产生任何细胞毒性和溶血作用。我们阐明 ENCC 如何在不同 pH、离子强度、离子类型和蛋白质浓度下提供卓越的生物解毒平台。这项研究的结果可能为开发下一代体外药物捕获添加剂和设备铺平道路。
Cancer is one of the leading causes of death worldwide, affecting millions of people every year. Although chemotherapy remains one of the most common cancer treatments in the world, the severe side effects of chemotherapy drugs impose serious concerns to cancer patients. In many cases, the chemotherapy can be localized to maximize the drug effects; however, the drug systemic circulation induces undesirable side effects. Here, we have developed a highly efficient cellulose-based nanoadsorbent that can capture more than 6,000 milligrams of doxorubicin (DOX), one of the most widely used chemotherapy drugs, per gram of the adsorbent at physiological conditions. Such drug capture capacity is more than 3,200% higher than other nanoadsorbents, such as DNA-based platforms. We show how anionic hairy cellulose nanocrystals, also known as electrosterically stabilized nanocrystalline cellulose (ENCC), bind to positively charged drugs in human serum and capture DOX immediately without imposing any cytotoxicity and hemolytic effects. We elucidate how ENCC provides a remarkable platform for biodetoxification at varying pH, ionic strength, ion type, and protein concentration. The outcome of this research may pave the way for developing the next-generationin vitroandin vivodrug capture additives and devices.